Mon, Sep 1, 2014, 3:46 AM EDT - U.S. Markets closed for Labor Day


% | $
Quotes you view appear here for quick access.

Advaxis, Inc. Message Board

  • investalot May 15, 2013 6:39 PM Flag

    go to the web site boys you hit a home run

    We achieved proof of concept with this Phase 2 study, and over the next two to five years, we plan to advance ADXS-HPV
    through registrational Phase 3 trials and regulatory approval(s) in the United States and relevant markets for the treatment of women
    with cervical cancer. We are currently evaluating this same Lm-LLO immunotherapy in Phase 1/2 clinical trials for two other HPVassociated
    cancers: head and neck cancer and anal cancer. In addition, we plan to advance ADXS-PSA, which is an Lm-LLO
    immunotherapy directed against prostate-specific antigen, or PSA, our second Lm-LLO immunotherapy, into a Phase 1 dose
    escalation trial to determine the maximum tolerated dose for the treatment of prostate cancer in the first half of 2014. We plan for this
    to be a dose escalation trial to evaluate safety and determine the maximum tolerated dose for the treatment of prostate cancer. A third
    Lm-LLO immunotherapy, ADXS-cHER2, is being evaluated for safety and efficacy in the treatment of companion dogs with human
    epidural growth factor receptor-2, or HER2, over-expressing osteosarcoma.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.88+0.15(+4.02%)Aug 29 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Hi-Crush Partners LP
NYSEFri, Aug 29, 2014 4:04 PM EDT
Synaptics Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT